Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03919617 · ClinicalTrials.gov registry record · Phase 1
Metabolic Pathways of GRA in Patients With Type 1 Diabetes
A Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03919617 is a Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 4 participants.
The verdict
NCT03919617, a Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
A pilot study for individuals with Type 1 Diabetes who are willing to add a GRA (Glucagon Receptor Antagonist) to their current Diabetes treatment regimen. There will be 10 study visits over the course of approximately 8 weeks, with 4 weeks of once weekly, subcutaneous GRA (REMD-477) injection. Testing includes 2 MRI scans, 2 glucose challenges, and 2 insulin withdrawal challenges along with physical assessments and vitals.
Interventions
- DRUG REMD-477
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03919617
The ClinicalTrials.gov registry entry for NCT03919617 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which REMD-477 is the first listed.
NCT03919617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03919617 about?
NCT03919617 is a clinical study titled "Metabolic Pathways of GRA in Patients With Type 1 Diabetes". A pilot study for individuals with Type 1 Diabetes who are willing to add a GRA (Glucagon Receptor Antagonist) to their current Diabetes treatment regimen. There will be 10 study visits over the course of approximately 8 weeks, with 4 weeks of once weekly, subcutaneous GRA (REMD-477) injection. Test...
What is the current status of trial NCT03919617?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2019-07-01. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT03919617?
The interventions under investigation include: REMD-477 (DRUG).
Who is sponsoring clinical trial NCT03919617?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.